Pfizer has agreed to purchase Metsera for up to USD 7.2 billion (including USD 4.9 billion upfront and USD 2.3 billion in contingent value rights tied to clinical and regulatory milestones) for obesity and cardiometabolic therapies. The acquisition adds weekly and monthly injectable GLP-1 receptor agonist MET-097i in Phase II trials, monthly amylin analogue MET-233i in Phase I studies and two oral GLP-1 candidates nearing clinical entry. Metsera's peptide engineering platform offers differentiated mechanisms targeting improved efficacy, tolerability and dosing convenience through combination approaches.

Pfizer CEO Albert Bourla highlighted Metsera's potential best-in-class injectable candidates demonstrating clinical advantages in efficacy persistence supporting monthly administration. The deal accelerates Pfizer's entry into obesity therapeutics leveraging its cardiometabolic expertise and global commercial infrastructure. Metsera's pipeline addresses over 200 obesity-related health conditions through nutrient-stimulated hormone therapies including GLP-1 agonists, amylin analogues and novel combinations targeting superior weight loss and metabolic benefits versus existing incretin therapies.

According to PharmCube's NextBiopharm® database, this is the fifth M&A transaction this year in the obesity space. Click here to request a free trial for NextBiopharm®.